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Food intake regulates energy balance, and its dysregulation leads to metabolic disorders, such as 
obesity and type 2 diabetes (T2D). During feeding, free fatty acids (FFAs) are not only essential 
nutrients but also act as signaling molecules in various cellular processes. Recently, several G protein-
coupled receptors (GPCRs) that act as FFA receptors (FFARs) have been identified; GPR41/FFAR3 
and GPR43/FFAR2 are activated by short-chain FFAs. GPR40/FFAR1, GPR119, and GPR120/FFAR4 
are activated by medium- and long-chain FFAs. FFARs are widely expressed and contribute to many 
important physiological functions in order to maintain energy homeostasis. Hence, these FFARs 
have come to be regarded as new drug targets for metabolic disorder such as obesity and T2D.
All articles in this topic highlight the interconnection between FFARs and the regulation of 
energy homeostasis. They also focused on essential role of FFARs in the pathogenesis of metabolic 
syndromes, such as obesity, insulin resistance, and T2D and discussed the potential of FFARs as 
drug target. These articles give valuable insight into unanswered questions in relation to this topic. 
First, recent studies demonstrate that short-chain free fatty acids (SCFAs) produced by microbiota 
fermentation act as signaling molecules through SCFAs receptors (SCFARs), such as GPR41 and 
GPR43 and influence the host’s metabolism (1–3). Hence, the gut microbiota can influence and 
play important roles in host physiology and pathology via these receptors. GPR41, which is 
expressed in adipose tissue, gut, and the peripheral nervous system, contributes SCFAs-dependent 
systemic energy regulation (1). In particular, GPR41 regulates host energy balance by modulating 
sympathetic activity and intestinal gluconeogenesis. GPR43, which is expressed in the adipose tis-
sue, intestines, and immune tissues, also contributes the regulation of energy homeostasis depends 
on SCFAs produced by gut microbiota (2). GPR43 deficiency induced obesity in mice, while mice 
that overexpress GPR43 only in adipose tissue were lean under normal conditions; both of these 
strains did not exhibit either phenotype under germ-free conditions or after antibiotic treatment. 
Furthermore, SCFA-mediated GPR43 activation suppressed adipose insulin signaling, leading to 
inhibition of fat accumulation in the adipose tissues, while unincorporated lipids and glucose were 
primarily utilized in muscles. The GPR43-insulin pathway has a key role in adipose tissue acting 
as an important physiological mechanism through which metabolic fuels regulate body energy 
balance (2, 3). These studies clearly showed the importance of SCFAs produced by microbiota and 
their receptors (1–3). Based on the importance and dynamic roles of microbiota in host physiol-
ogy, Pluznick pointed out a complex interplay between the genetics of the microbiota and that 
of the host organism (4). Researchers should consider the contribution of these microorganisms 
and their metabolites because there are many examples of phenotypes that were not easily to 
replicated by other groups may be due to the influence of variations of gut microbiota (4). Second, 
medium-chain fatty acids (MCFAs) and long-chain fatty acids (LCFAs) are not only essential 
nutrient, but also act as ligands of GPR40/FFAR1 and GPR120/FFAR4 and regulate systemic 
energy homeostasis (5–8). GPR40 is highly expressed in pancreatic β cells and intestine. GPR40 
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augment glucose-stimulated insulin secretion after acute expo-
sure to LCFAs by stimulation of not only insulin secretion from 
pancreatic β cells directly, but also incretin hormones, such as 
glucagon like peptide-1 (GLP-1), gastric inhibitory polypeptide 
(GIP) and cholecystokinin (CCK) from intestine (5, 8). The 
activation of GPR120 by ω-3 FFAs mediated anti-inflammatory 
effect of ω-3 FFAs as described in the articles by Oh et al. (7). This 
effect is associated with the suppression of Toll-like receptor via 
β-arrestin2 signaling pathway and transforming growth factor-β 
activated kinase 1 (TAK1) involved in TNF-α inflammation 
signaling pathway. Furthermore, both a gene deficiency in 
mice and non-synonymous functional-loss mutation of human 
GPR120 are associated with obesity, which was accompanied 
with decreased differentiation and lipogenesis (6). Hence, 
selective synthetic ligands for FFARs have consequently been 
developed as potential treatments for metabolic syndrome (9). 
Particularly, clinical studies show that TAK875/Fasiglifam, an 
agonist of GPR40 improved glucose metabolism with a reduced 
risk of hypoglycemia, although this ligand was dropped from 
clinical trials due to potential liver toxicity. Activation of each 
of GPR41, 43, and 120 has also been suggested to have potential 
benefits for metabolic function (9).
Overall, all the review articles provided a comprehensive 
overview of the energy regulation by FFARs and a new prospect 
for treatment of metabolic disorder such as obesity and type 2 
diabetes.
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